<DOC>
	<DOCNO>NCT02575066</DOCNO>
	<brief_summary>Radiotherapy ( RT ) alone able induce clinically significant effect variable pathologic response ( pathological complete remission , pCR , define ≥ 95 % , ≤ 5 % remain visible tumour cell ) 10 % case . A prior phase I study ( PASART-1 ; NCT01985295 ) suggest 25 x 2 Gy preoperative RT combination daily 800mg oral pazopanib feasible , induce tissue replace tumor consist fibrosis necrosis 40 % thus treated patient .</brief_summary>
	<brief_title>Clinical Study Concurrent Pazopanib Radiotherapy Non-metastatic Sarcoma Patients</brief_title>
	<detailed_description>Patient receive concurrent radiotherapy ( 25x2Gy ) pazopanib ( QD 800 mg )</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Histologically confirm newly diagnose intermediate high grade soft tissue sarcoma localize extremity , trunk chest wall head neck area , standard treatment combination radiotherapy surgery ( deep seat , &gt; 5cm accord RECIST 1.1 criterion and/or anticipate close resection margin , grade II/III accord WHO definition ) Age ≥ 18 year WHO performance status ≤ 1 Able willing undergo blood sample PK PD analysis Able swallow retain oral medication Able willing undergo MRI scan Able willing undergo tumor biopsy Adequate organ function describe laboratory finding table 1 . For thyroid function , T4 TSH value must within normal value range participate center Written inform consent prior performance studyspecific procedures assessment must willing comply treatment follow . Exclusion Criteria Prior malignancy ; except another malignancy diseasefree ≥ 5 year , completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma . Patients recurrent sarcoma ( even without prior radiotherapy ) Ewing sarcoma PNET family tumor , rhabdomyosarcoma ( pediatric adult ) , osteosarcoma Clinically significant gastrointestinal abnormality might interfere oral dose diagnose Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥140 mmHg diastolic blood pressure ( DBP ) ≥ 90mmHg ] Unstable serious concurrent condition ( e.g. , active infection require systemic therapy ) Prolongation correct QT interval ( QTc ) &gt; 480 msec ECG History follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Symptomatic peripheral vascular disease Coronary artery bypass graft surgery Class II , III IV congestive heart failure define New York Heart Association ( NYHA ) History cerebrovascular accident , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month Macroscopic hematuria Hemoptysis clinically relevant within 4 week first dose pazopanib Evidence active bleeding bleeding diathesis Prior major surgery trauma within 28 day prior first dose study medication and/or presence nonhealing wound , fracture , ulcer Chemotherapy radiation therapy within 2 week prior first dose study medication Biological therapy treatment investigational agent within 28 day five halflives , whichever long prior first dose study medication Prohibited medication list protocol 14 day five halflives drug ( whichever longer ) prior visit 1 duration study Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Female patient pregnant , breastfeed male female patient reproductive potential employ effective method birth</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>pazopanib</keyword>
	<keyword>radiotherapy</keyword>
</DOC>